Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Trinity Biotech (TRIB) EPS (Weighted Average and Diluted) (2021 - 2022)

Trinity Biotech's EPS (Weighted Average and Diluted) history spans 2 years, with the latest figure at -$51.08 for Q2 2022.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 160.97% to -$51.08 in Q2 2022 year-over-year; TTM through Jun 2022 was -$51.08, a 160.97% decrease, with the full-year FY2025 number at -$2.0, down 11.11% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$51.08 in Q2 2022 for Trinity Biotech, down from -$19.58 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for TRIB hit a ceiling of -$19.58 in Q2 2021 and a floor of -$51.08 in Q2 2022.